About Olaris
Olaris is a company based in Waltham (United States) founded in 2014 by Liz Oday. Olaris has raised $62.5 thousand across 5 funding rounds from investors including LabCorp, Bruker and The Michael J. Fox Foundation. The company has 9 employees as of December 31, 2022. Olaris offers products and services including Cerebro Services. Olaris operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Personalis, among others.
- Headquarter Waltham, United States
- Employees 9 as on 31 Dec, 2022
- Founders Liz Oday
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Olaris, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$62.5 K (USD)
in 5 rounds
-
Latest Funding Round
Not available
-
Investors
LabCorp
& 9 more
-
Employee Count
9
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Olaris
Olaris offers a comprehensive portfolio of products and services, including Cerebro Services.
Offers metabolomics-based tools for identifying biomarkers of response in patients.
People of Olaris
Unlock access to complete
Unlock access to complete
Funding Insights of Olaris
Olaris has successfully raised a total of $62.5K across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Olaris
Olaris has secured backing from 10 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include LabCorp, Bruker and The Michael J. Fox Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on AI, healthcare, life science, B2B enterprise, and technology sectors
|
Locked | Locked | Locked | |
|
Venture capital investing and portfolio management services for accredited investors.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Olaris
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Olaris
Investment portfolio details for Olaris
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Olaris
Detailed financials for Olaris
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Olaris Comparisons
Peer comparison for Olaris
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Olaris
Olaris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Personalis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Detailed competitors of Olaris
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Olaris
Complete news archive for Olaris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Olaris
Olaris was founded in 2014 and raised its 1st funding round 4 years after it was founded.
Olaris is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Liz Oday is the current CEO of Olaris. They have also founded this company.
Olaris is a funded company, having raised a total of $62.5K across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Olaris is 9.
Olaris was founded in 2014 and is headquartered in Waltham, United States. In-vitro diagnostics are developed by the company for oncology, solid-organ transplantation, and neurodegeneration. A high-throughput metabolomics platform integrated with machine learning is utilized to identify metabolite signatures. These tools support precision medicine applications within the biotechnology sector. Operations focus on diagnostic solutions for clinical needs in these therapeutic areas.
Olaris's top competitors include Juno Therapeutics, Personalis and Poseida Therapeutics.
Olaris offers Cerebro Services.
Olaris has 10 investors. Key investors include LabCorp, Bruker, The Michael J. Fox Foundation, Robert Carpenter, and Innospark.